Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome)

Henry T. Lynch, Thomas Smyrk, Jane F. Lynch

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) predisposes to cancers of the colon, endometrium and several other extra-colonic sites in the absence of premonitory physical stigmata (Muir-Torre syndrome excepted). Discovery of the several DNA mismatch repair genes (hMSH2, hMLH1, hPMS1, hPMS2) holds the potential for determining the cancer destiny of patients, theoretically in utero. Pre-symptomatic DNA testing is now possible in patients from HNPCC families and will be clinically available once inexpensive and simple tests for these germ-line mutations have been effected. Genetic counseling will be mandatory, given the myriad socio-psychological, insurance, and potentially other personal issues which may impact this knowledge. New findings in the pathology of HNPCC, particularly an increased frequency of interval cancers and the likely accelerated rate of the adenoma to cancer sequence, indicate the need for more frequent colonoscopic surveillance with an option for prophylactic subtotal colectomy in germ-line-positive individuals.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalInternational Journal of Cancer
Volume69
Issue number1
DOIs
StatePublished - Feb 20 1996

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Natural History
Molecular Biology
Colorectal Neoplasms
Pathology
Muir-Torre Syndrome
Christianity
Neoplasms
DNA Mismatch Repair
Colectomy
Germ-Line Mutation
Genetic Counseling
Endometrial Neoplasms
Insurance
Germ Cells
Adenoma
Colonic Neoplasms
Psychology
DNA
Genes

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). / Lynch, Henry T.; Smyrk, Thomas; Lynch, Jane F.

In: International Journal of Cancer, Vol. 69, No. 1, 20.02.1996, p. 38-43.

Research output: Contribution to journalArticle

@article{69c67b4142da46818d2c2736c72c47be,
title = "Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome)",
abstract = "Hereditary non-polyposis colorectal cancer (HNPCC) predisposes to cancers of the colon, endometrium and several other extra-colonic sites in the absence of premonitory physical stigmata (Muir-Torre syndrome excepted). Discovery of the several DNA mismatch repair genes (hMSH2, hMLH1, hPMS1, hPMS2) holds the potential for determining the cancer destiny of patients, theoretically in utero. Pre-symptomatic DNA testing is now possible in patients from HNPCC families and will be clinically available once inexpensive and simple tests for these germ-line mutations have been effected. Genetic counseling will be mandatory, given the myriad socio-psychological, insurance, and potentially other personal issues which may impact this knowledge. New findings in the pathology of HNPCC, particularly an increased frequency of interval cancers and the likely accelerated rate of the adenoma to cancer sequence, indicate the need for more frequent colonoscopic surveillance with an option for prophylactic subtotal colectomy in germ-line-positive individuals.",
author = "Lynch, {Henry T.} and Thomas Smyrk and Lynch, {Jane F.}",
year = "1996",
month = "2",
day = "20",
doi = "10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X",
language = "English",
volume = "69",
pages = "38--43",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome)

AU - Lynch, Henry T.

AU - Smyrk, Thomas

AU - Lynch, Jane F.

PY - 1996/2/20

Y1 - 1996/2/20

N2 - Hereditary non-polyposis colorectal cancer (HNPCC) predisposes to cancers of the colon, endometrium and several other extra-colonic sites in the absence of premonitory physical stigmata (Muir-Torre syndrome excepted). Discovery of the several DNA mismatch repair genes (hMSH2, hMLH1, hPMS1, hPMS2) holds the potential for determining the cancer destiny of patients, theoretically in utero. Pre-symptomatic DNA testing is now possible in patients from HNPCC families and will be clinically available once inexpensive and simple tests for these germ-line mutations have been effected. Genetic counseling will be mandatory, given the myriad socio-psychological, insurance, and potentially other personal issues which may impact this knowledge. New findings in the pathology of HNPCC, particularly an increased frequency of interval cancers and the likely accelerated rate of the adenoma to cancer sequence, indicate the need for more frequent colonoscopic surveillance with an option for prophylactic subtotal colectomy in germ-line-positive individuals.

AB - Hereditary non-polyposis colorectal cancer (HNPCC) predisposes to cancers of the colon, endometrium and several other extra-colonic sites in the absence of premonitory physical stigmata (Muir-Torre syndrome excepted). Discovery of the several DNA mismatch repair genes (hMSH2, hMLH1, hPMS1, hPMS2) holds the potential for determining the cancer destiny of patients, theoretically in utero. Pre-symptomatic DNA testing is now possible in patients from HNPCC families and will be clinically available once inexpensive and simple tests for these germ-line mutations have been effected. Genetic counseling will be mandatory, given the myriad socio-psychological, insurance, and potentially other personal issues which may impact this knowledge. New findings in the pathology of HNPCC, particularly an increased frequency of interval cancers and the likely accelerated rate of the adenoma to cancer sequence, indicate the need for more frequent colonoscopic surveillance with an option for prophylactic subtotal colectomy in germ-line-positive individuals.

UR - http://www.scopus.com/inward/record.url?scp=0029915034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029915034&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X

DO - 10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X

M3 - Article

VL - 69

SP - 38

EP - 43

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -